The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will consist of a brief interaction with the subject or parent or guardian to obtain consent, collect a blood sample, medical history, and physical examination of those who meet the inclusion criteria. The blood sample will be tested for the WBC value, as well as processed into plasma in order to compute the APPY1 Test result based on a combination of the WBC value and CRP marker test results from the APPY1 Test cassette. There will be a 2-week (14 days +/- 3) follow-up telephone call for those subjects that were discharged from the ED without an appendectomy or diagnosis of acute appendicitis. Use of the APPY1 Test to help identify low risk patients could significantly reduce the use of CT scans in diagnosis of AA, thereby reducing the exposure to ionizing radiation in children, adolescents, and young adults.
| Condition |
|---|
|
Acute Appendicitis |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis in Children, Adolescents, and Young Adults Presenting to the Emergency Department |
- Sensitivity, Specificity, Negative and Positive Predictive Value [ Time Frame: Upon 3rd party review of data ] [ Designated as safety issue: No ]95% confidence intervals on Sensitivity and Specificity
- CT utilization [ Time Frame: Upon 3rd party review of data ] [ Designated as safety issue: No ]CT utilization behaviors based on questions posed to the physicians about their current imaging intentions and those intentions were an APPY1 Test result available
Biospecimen Retention: Samples Without DNA
Surplus plasma samples will be retrieved by the Sponsor for future development of protein biomarkers.
| Estimated Enrollment: | 2200 |
| Study Start Date: | October 2012 |
Eligibility| Ages Eligible for Study: | 2 Years to 20 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Children, adolescents and young adults 2 to 20 years old.
Inclusion Criteria:
- > 2 years old to < 20 years old (up until the 21st birthday),
- Right lower quadrant or poorly localized abdominal pain, or tenderness that includes the right lower quadrant, with other features including, but not limited to, nausea, vomiting, and/or anorexia, requiring acute appendicitis to be added to the differential,
- Onset of abdominal pain within 72 hours or less,
- Patients of either gender may participate and,
- Patient or accompanying parent or guardian is able to read and understand study documentation and to provide informed consent.
Exclusion Criteria:
- History includes prior appendectomy,
- Subjects whose presentation history and physical examination place them at such high risk of acute appendicitis that it would be clinically reasonable to proceed with exploratory laparotomy and/or appendectomy without advanced imaging,
- Treatment with any immunosuppressive medication or chemotherapeutic agents within 28 days, or systemic steroids (oral or intravenous) within 14 days,
- History of end-stage, metastatic cancer or an active immune disorder,
- History includes abdominal trauma or invasive abdominal procedures/surgery within the previous two weeks,
- Patients who have received diagnostic imaging (CT, MRI, or US) for abdominal pain in the previous two weeks,
- Patients with report of abdominal pain greater than 72 hours,
- History of active bleeding disorder, which may complicate phlebotomy or placement of peripheral IV catheter,
- Participation in a research study within the previous 30 days,
- Vulnerable populations including prisoners of an adult or juvenile detention center, and
- Subject, parent or guardian unable to provide informed consent.
Contacts and Locations| Contact: Joel Hale | 512-300-1568 | jhale@venaxis.com |
| Contact: Joe Gogain, PhD | 303-794-2000 ext 228 | jgogain@venaxis.com |
Show 25 Study Locations| Principal Investigator: | Dave Huckins, MD | Newton-Wellesley Hospital |
More Information
No publications provided
| Responsible Party: | Venaxis, Inc. |
| ClinicalTrials.gov Identifier: | NCT01652170 History of Changes |
| Other Study ID Numbers: | CP12-001 |
| Study First Received: | July 25, 2012 |
| Last Updated: | May 7, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Appendicitis Acute Disease Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |
Cecal Diseases Intestinal Diseases Disease Attributes Pathologic Processes |
ClinicalTrials.gov processed this record on May 21, 2013